share_log

Morgan Stanley Maintains Equal-Weight on Blueprint Medicines, Raises Price Target to $115

Morgan Stanley Maintains Equal-Weight on Blueprint Medicines, Raises Price Target to $115

大摩资源lof维持Blueprint Medicines等权重,并将目标价格提高至115美元。
Benzinga ·  07/12 13:18

Morgan Stanley analyst Michael Ulz maintains Blueprint Medicines (NASDAQ:BPMC) with a Equal-Weight and raises the price target from $110 to $115.

大摩资源lof的分析师Michael Ulz认为Blueprint Medicines (纳斯达克:BPMC) 评级为等权重并将目标价从110美元上调至115美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发